| [1] |
Broers J L, Ramaekers F C, Bonne G, et al. Nuclear lamins: laminopathies and their role in premature ageing[J]. Physiol Rev, 2006, 86(3): 967-1008.
|
| [2] |
Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease[J]. N Engl J Med, 1999, 341(23): 1715-1724.
|
| [3] |
Worman H J, Fong L G, Muchir A, et al. Laminopathies and the long strange trip from basic cell biology to therapy[J]. J Clin Invest, 2009, 119(7): 1825-1836.
|
| [4] |
van Berlo J H, de Voogt W G, van der Kooi A J, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death [J]. J Mol Med (Berl), 2005, 83(1): 79-83.
|
| [5] |
Hasselberg N E, Haland T F, Saberniak J, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation[J]. Eur Heart J, 2018, 39(10): 853-860.
|
| [6] |
Nishiuchi S, Makiyama T, Aiba T, et al. Gene-based risk stratification for cardiac disorders in LMNA mutation carriers[J]. Circ Cardiovasc Genet, 2017, 10(6): e001603.
|
| [7] |
Rosario K F, Karra R, Amos K, et al. LMNA cardiomyopathy: important considerations for the heart failure clinician[J]. J Card Fail, 2023, 29(12): 1657-1666.
|
| [8] |
Bank E M, Ben-Harush K, Feinstein N, et al. Structural and physiological phenotypes of disease-linked lamin mutations in C. elegans[J]. J Struct Biol, 2012, 177(1): 106-112.
|
| [9] |
Ito M, Katoh M, Sassa T, et al. LMNA Q353R mutation causes dilated cardiomyopathy through impaired vitamin D signaling[J]. Circulation, 2024, 150(12): 971-974.
|
| [10] |
Lee J, Termglinchan V, Diecke S, et al. Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy[J]. Nature, 2019, 572(7769): 335-340.
|
| [11] |
Mounkes L C, Kozlov S V, Rottman J N, et al. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice[J]. Hum Mol Genet, 2005, 14(15): 2167-2180.
|
| [12] |
Markandeya Y S, Tsubouchi T, Hacker T A, et al. Inhibition of late sodium current attenuates ionic arrhythmia mechanism in ventricular myocytes expressing LaminA-N195K mutation[J]. Heart Rhythm, 2016, 13(11): 2228-2236.
|
| [13] |
Laurini E, Martinelli V, Lanzicher T, et al. Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins[J]. Cardiovasc Res, 2018, 114(6): 846-857.
|
| [14] |
Neubauer S. The failing heart: an engine out of fuel[J]. N Engl J Med, 2007, 356(11): 1140-1151.
|
| [15] |
Lazaropoulos M P, Elrod J W. Mitochondria in pathological cardiac remodeling[J]. Curr Opin Physiol, 2022, 25: 100489.
|
| [16] |
Doenst T, Nguyen T D, Abel E D. Cardiac metabolism in heart failure: implications beyond ATP production[J]. Circ Res, 2013, 113(6): 709-724.
|
| [17] |
Scuruchi M, Mannino F, Imbesi C, et al. Biglycan involvement in heart fibrosis: modulation of adenosine 2A receptor improves damage in immortalized cardiac fibroblasts[J]. Int J Mol Sci, 2023, 24(2): 1784.
|
| [18] |
Wei K, Serpooshan V, Hurtado C, et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart[J]. Nature, 2015, 525(7570): 479-485.
|
| [19] |
Peters M C, di Martino S, Boelens T, et al. Follistatin-like 1 promotes proliferation of matured human hypoxic iPSC-cardiomyocytes and is secreted by cardiac fibroblasts[J]. Mol Ther Methods Clin Dev, 2022, 25: 3-16.
|
| [20] |
Koenig A L, Shchukina I, Amrute J, et al. Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure[J]. Nat Cardiovasc Res, 2022, 1(3): 263-280.
|
| [21] |
Qian C, Dong G L, Yang C M, et al. Broadening horizons: molecular mechanisms and disease implications of endothelial-to-mesenchymal transition[J]. Cell Commun Signal, 2025, 23(1): 16.
|
| [22] |
Kovacic J C, Dimmeler S, Harvey R P, et al. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2019, 73(2): 190-209.
|
| [23] |
Souders C A, Bowers S L, Baudino T A. Cardiac fibroblast: the renaissance cell[J]. Circ Res, 2009, 105(12): 1164-1176.
|
| [24] |
Kedzierski R M, Yanagisawa M. Endothelin system: the double-edged sword in health and disease[J]. Annu Rev Pharmacol Toxicol, 2001, 41: 851-876.
|
| [25] |
Oka T, Xu J, Kaiser R A, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling[J]. Circ Res, 2007, 101(3): 313-321.
|
| [26] |
Braile M, Marcella S, Cristinziano L, et al. VEGF-A in cardiomyocytes and heart diseases[J]. Int J Mol Sci, 2020, 21(15): 5294.
|
| [27] |
Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies[J]. Genes Cancer, 2011, 2(12): 1097-1105.
|
| [28] |
Aumailley M. The laminin family[J]. Cell Adh Migr, 2013, 7(1): 48-55.
|
| [29] |
Guo C, Willem M, Werner A, et al. Absence of α7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy[J]. Hum Mol Genet, 2006, 15(6): 989-998.
|
| [30] |
Israeli-Rosenberg S, Manso A M, Okada H, et al. Integrins and integrin-associated proteins in the cardiac myocyte[J]. Circ Res, 2014, 114(3): 572-586.
|